With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with a transaction set to propel the company into the CDMO market.

Meanwhile, Jabil’s market share has declined slightly from 5.3% in 2027 to 4.9% in 2024. We noted that Jabil’s revenue in 2024 has experienced the highest decline among competitors ...

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer support for drug development customers. The acquisition of Pii enhances ...

Jabil (JBL – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Ruplu Bhattacharya from Bank of America Securities reiterated a Buy rating on ...